Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ossium Health Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, meaning each pending matter is being reviewed by a different individual. Both of these applications are located within 1 distinct art unit, centralizing the technical review process. This concentration in 1 distinct art unit suggests that the pending matters are technically similar despite the involvement of multiple examiners.
The busiest examiner for the portfolio is TIWARI, VYOMA SHUBHAM, who is managing 1 pending office action. This workload is identical to the other examiner involved in the company's current prosecution. Because there are 2 distinct examiners for 2 total actions, the workload is distributed evenly. The focus of 2 pending office actions within 1 distinct art unit indicates that the Biotechnology & Pharmaceuticals applications share a closely related technical focus at the patent office, requiring consistent arguments across both files.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 32.1% | +47.4% |
| KNIGHT, TERESA E | 1 | 66.1% | +48.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18913087 | SYNCHRONIZED MESENCHYMAL STROMAL CELLS | TIWARI, VYOMA SHUBHAM | — |
| 18545891 | PERMEATION OF WHOLE VERTEBRAL BODIES WITH A CRYOPROTECTANT USING VACUUM ASSISTED DIFFUSION | KNIGHT, TERESA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18913087 | SYNCHRONIZED MESENCHYMAL STROMAL CELLS | TIWARI, VYOMA SHUBHAM | — |
| 18545891 | PERMEATION OF WHOLE VERTEBRAL BODIES WITH A CRYOPROTECTANT USING VACUUM ASSISTED DIFFUSION | KNIGHT, TERESA E | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18913087 | SYNCHRONIZED MESENCHYMAL STROMAL CELLS | TIWARI, VYOMA SHUBHAM | 1634 | §101§102 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18545891 | PERMEATION OF WHOLE VERTEBRAL BODIES WITH A CRYOPROTECTANT USING VACUUM ASSISTED DIFFUSION | KNIGHT, TERESA E | 1634 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOssium Health Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Vyoma Shubham Tiwari has the most, with 1 of Ossium Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
